Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander

Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander

Sammy Place, François Mastroianni, Vincent Colombie, Géraldine Claes, Axelle Gilles, Frédéric Vandergheynst

Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context.

2020

covid-19, SARS-CoV-2, G6PD deficiency, haemolytic anaemia

10.12890/2020_001875

Epidemiology and Health

Korean Society of Epidemiology

Medicine